Loan & DebtApr 7, 2026, 06:06 AM
Opus Genetics Enters $155 Million Senior Secured Note Purchase Agreement
AI Summary
Opus Genetics has entered into a senior secured note purchase agreement for up to $155 million with OPCM SA LLC and other purchasers. The agreement includes an initial committed tranche of $105 million, with the remaining $50 million uncommitted, providing Opus Genetics with significant funding for its operations and pipeline development.
Key Highlights
- Opus Genetics secures up to $155 million in senior secured notes.
- Initial committed tranche of $105 million, with $35 million funded on April 20, 2026.
- Subsequent tranches are contingent on milestones, including FDA Application Acceptance and Approval for OPGx-LCA5.